Fig. 7. AgomiR-425 treatment reduced MPTP-induced necroptosis and behavioral deficits.

a Study design of miR-425 intracranial injection in an MPTP mouse model. b FAM immunofluorescence tracing of injected AgomiR-425 in the SNpc of mice. c Fluorescence ISH of miR-425 expression after AgomiR-425 or scramble control injection in the SNpc of mice. d Immunohistochemistry for TH in the striatum and SN of AgomiR-425-injected mice and scramble-injected mice. Quantification of TH-positive neuronal fibers in the striatum and TH-positive neurons in the SNpc. e Representative images and quantification of immunohistochemistry for RIPK1 in dopaminergic neurons. f Representative images and quantification of immunohistochemistry for pMLKL in dopaminergic neurons. g Representative confocal micrographs and quantification of GFAP staining in the SNpc. h Quantification of TNFα level using ELISA. i Quantification of dopamine by HPLC in the striatum. j Representative tracks of mice in the open field chamber over 5 min. k, l Central-area distance and whole-area distance were measured. m Time spent on the rotarod for MPTP-induced Mir-425^low and WT mice was measured. All data represent the mean ± SEM. Student’s t test, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, not significant